|
|
|
| Effect of Intraperitoneal Bevacizumab Combined with Intraperitoneal Hyperthermic Perfusion Chemotherapy on APE1 / Ref-1 Gene Expression in Ovarian Cancer Patients |
| LI Shao-xing |
| The First Affliated Hospital of Chengdu Medical School,Sichuan Chengdu 610500 |
|
|
|
Abstract 【Objective】To explore the application of intraperitoneal bevacizumab (abdominal Neibeifazhu monoclonal antibody) combined with intraperitoneal hyperthermic perfusion chemotherapy in ovarian cancer patients and to detect the changes of APE1/Ref-1 gene expression before and after the treatment. 【Methods】Eighty cases of ovarian cancer were randomly divided into control group (n=40) and observation group (n=40). Two groups of patients were treated with paclitaxel and carboplatin chemotherapy. Patients in the control group received intraperitoneal hyperthermic perfusion chemotherapy treatment, and patients in the observation group received intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal bevacizumab (Neibeifazhu monoclonal antibody). The clinical efficacy and APE1/Ref-1 gene expression were compared between the two groups.【Results】After 4 weeks of treatment, the curative effect of the observation group was 90%, which was higher than that of the control group (67.50%), and the difference was significant (P<0.05). The adverse reaction rate had no significant difference between the observation group (6/40, 15%) and control group(7/40,17.5%) (P>0.05). Real-time PCR showed that APE1/Ref-1 gene expression was significantly increased after treatment in the two groups compared to that before treatment. The changes of APE-1/Ref-1 expression level in the observation group was significantly higher than that in the control group (P<0.05). 【Conclusion】Compared to intraperitoneal hyperthermic perfusion alone, the clinical effect of bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in ovarian cancer patients is better. During this combo treatment, APE1/Ref-1 gene expression was significantly enhanced in ovarian cancer tissues to improve the sensitivity to chemotherapy. It is worthy of popularization and application.
|
|
Received: 31 October 2016
|
|
|
|
|
|
[1] Huang X,Jian W,Wu Z,et al. Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation[J].Oncotarget,2014,5(14):5570.
[2] 田欣,张振勇,吴丽娜,等.洛铂腔内灌注治疗恶性胸腹腔积液的临床观察[J].临床肿瘤学杂志,2013,18(8):740-742.
[3] 梁秀菊,楚慧丽,王俊,等.多西他赛联合腹腔热灌注化疗加热疗治疗晚期卵巢癌[J].中国肿瘤临床,2013,40(17):1051-1054.
[4] 简萍,李斌,衣倩红.腹腔内热灌注化疗治疗卵巢恶性肿瘤的临床观察[J].中国妇幼保健,2013,28(12):1974-1977.
[5] 卢玉兰,李蓁,李雁,等.细胞减灭术中腹腔热灌注化疗治疗卵巢癌Ⅲc期的疗效观察[J].武汉大学学报:医学版,2015,36(4):562-567.
[6] 张西愿,徐小博,马向东,等.贝伐珠单抗治疗上皮性卵巢癌的临床研究进展[J].现代妇产科进展,2014,23(6):489-492.
[7] 林仲秋,谢玲玲,李晶.FIGO2013卵巢癌、输卵管癌、腹膜癌新分期解读[J].中国实用妇科与产科杂志,2013,(12):921-923.
[8] Li L. The activation of TLR7 regulates the expression of VEGF,TIMP1,MMP2,IL -6,and IL-15 in Hela cells [J].Mol Cell Biochem,2014,389(1-2):43-49.
[9] 徐邱鸿,逯庆玲,陈洪宇,等. 骨桥蛋白促进SKOV3 卵巢癌细胞增殖、迁移及侵袭能力[J].中国现代医生, 2014, 52( 36) : 1-4,8.
[10] Kala S,Mak AS,Liu X,et al. Combination of dendrimer-nanovector-mediated small interfering RNA delivery to target Akt with the clinical anticancer drug paclitaxel for effective and potent anticancer activity in treating ovarian cancer [J].J Med Chem,2014,57(6): 2634-2642.
[11] 董禹洋. 腹腔内贝伐珠单抗联合腹腔热灌注化疗治疗卵巢癌腹腔积液的临床观察[J].中国冶金工业医学杂志,2013,30(6): 665-667.
[12] Maturu VN,Singh N,Bansal P,et al. Combination of intravitreal bevacizumab and systemic therapy for choroidal metastases from lung cancer: report of two cases and a systematic review of literature[J].Med Oncol,2014,31(4):901.
[13] 张丽丽, 吕秀萍. 腹腔热灌注化疗联合贝伐珠单抗治疗卵巢癌腹腔积液的疗效及生活质量评价[J].中国肿瘤临床与康复, 2016(6):753-756.
[14] 李然, 赵冰清, 张艳华. 贝伐珠单抗治疗恶性肿瘤的不良反应分析[J].中国新药杂志, 2013(17):129-134.
[15] 卢建华,罗琨,冯梦宇,等.BRIT1通过调控p53蛋白的表达发挥肿瘤抑制作用的实验研究[J].中华实验外科杂志,2014,31(9):1926-1928. |
|
|
|
2017, Vol. 34 
